Overdiagnosis Raises Concerns as the Incidence of Thyroid Cancer Cases Rises GloballyAugust 18th 2020
Experts suspect the rising incidence of thyroid cancer may be related to the growing scrutiny of the thyroid gland with ultrasonography or other diagnostic techniques, but overdiagnosis may be a growing factor in the field.
Larotrectinib Efficacy Highlights Importance of Genomic Testing in Thyroid CancerAugust 18th 2020
Marcia Brose, MD, PhD, discusses how the thyroid cancer treatment landscape will be impacted by the positive findings regarding larotrectinib in the presence of a TRK fusion.
Pazopanib Activity in RAI-Refractory Differentiated Thyroid Cancer Corroborated in Prospective StudyAugust 14th 2020
Pazopanib was confirmed active with manageable toxicities as treatment of patients with progressive radioactive-iodine–refractory differentiated thyroid cancer, based on results of a prospective study.
Lenvatinib Starting Dose Confirmed for Refractory RAI-Refractory DTC IndicationAugust 11th 2020
A phase 2 clinical trial of radioactive iodine–refractory differentiated thyroid cancer demonstrated that the lenvatinib starting dose of 24 mg is superior to the lower dose of 18 mg, missing the noninferiority primary end point of the study.
FDA Approval Sought for Pralsetinib in RET+ Medullary Thyroid CancerJuly 1st 2020
"Pralsetinib has broad potential to address the medical needs of patients with RET-altered cancers, who have not traditionally benefited from targeted therapy even though their tumors have a known disease driver."
Encouraging Larotrectinib Data Underscores Importance of Genetic Testing in Metastatic Solid TumorsJune 18th 2020
In an interview with Targeted Oncology, Marcia Brose, MD, PhD, discussed the importance of conducting genetic testing on all patients with metastatic solid tumors following the exciting data on larotrectinib.
Phase 2 Study Spurs Hope for Future Combination Trials in Anaplastic Thyroid CancerJune 9th 2020
“Due to a lack of efficacy observed with lenvatinib monotherapy in anaplastic thyroid cancer, further investigation of lenvatinib in combination with a checkpoint inhibitor may be warranted rather than pursuing further lenvatinib as a single agent.”
Targeted Therapy Plus Immunotherapy Combos Inspire Hope in Anaplastic Thyroid CancerMay 28th 2020
In an interview with Targeted Oncology, Maria E. Cabanillas, MD, discussed the findings from a clinical trial evaluating potential atezolizumab combinations in patients with anaplastic thyroid cancer.
FDA Grants Pembrolizumab Priority Review for TMB-High TumorsApril 7th 2020
The FDA has accepted and granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high who have progressed following prior treatment and who have no satisfactory alternative treatment options.
Chemotherapy Toxicity Correlates With Nutritional Factors in Solid TumorsMarch 30th 2020
An association was found between a lower risk of grade 3 or higher chemotherapy toxicity with higher body mass indexes and normal albumin, a protein made in the liver, levels in older adult patients with solid tumors, according to an analysis of a prospective, multicenter study.
COVID-19 Presents an Opportunity for Precision Medicine to Play Expanded Role in CareMarch 30th 2020
A sudden surge in the cases of COVID-19 due to pandemic, along with efforts to contain it, has led to multiple challenges that no country has experienced in the last several decades. The global pandemic from COVID-19 poses a unique set of challenges not only for patients with cancer who need their treatment, but also for caregivers, oncologists, and the overall care team.
South Carolina Oncology Practice Continues Cautious Operation Amidst the COVID-19 PandemicMarch 23rd 2020
In an interview with Targeted Oncology, Kashyap Patel, MD, discussed the COVID-19 pandemic and the implementation of new precautions in his practice as the number of COVID-19 infected persons rises in the state.<br />
Benefit of PARP Inhibitors May Extend to Certain Tumors With IDH MutationsMarch 21st 2020
Patients harboring IDH1/2 muta­tions may receive benefit by the use of PARP inhibitors, with investigators initi­ating clinical trials in patients across multiple different tumor types to determine the efficacy of this strategy.
Pembrolizumab Monotherapy Elicits Responses in Patients With Advanced Rare CancersMarch 20th 2020
Treatment with pembrolizumab demonstrated antitumor activity along with tolerable toxicity in patients with 4 different rare and hard-to-treat malignancies, according to results from a phase II study led by The University of Texas MD Anderson Cancer Center researchers and published in the Journal for ImmunoTherapy of Cancer.